

2723-517 5

Molecular mechanisms of drug action

Second Edition

Christopher J. Coulson

Glaxo Group Research, UK



Contents

Preface	xi
Preface to second edition	xiii
Glossary	xv
1. General principles	1
1.1 Background	1
1.2 Do drugs have a specific mode of action?	1
1.3 Basic processes	2
1.4 Drug binding to enzymes	3
1.5 Drug binding to receptors	5
1.6 Further considerations	6
1.7 Partition coefficient	7
1.8 Drug nomenclature	8
1.9 Stereochemistry	9
1.10 The future	11
References	11
2. Nucleic acid biosynthesis and catabolism	13
2.1 Introduction	13
2.1.1 Overall scheme	15
2.2 Nucleotide biosyntheses - enzyme targets of drugs	18
2.2.1 Dihydroorotate dehydrogenase - actovaquone as antimalarial	18
2.2.2 Dihydropteroate synthetase - sulphonamides as anti-bacterials	19
2.2.3 Dihydrofolate reductase - trimethoprim and pyrimethamine as anti-bacterials, methotrexate as anti-cancer	21
2.2.4 Ribonucleotide reductase - hydroxyurea as anti-cancer	23
2.2.5 Thymidylate synthetase - 5-fluorouracil as anti-cancer, 5-fluorocytosine as anti-fungal	25

2.2.6	Inosine monophosphate dehydrogenase - ribavirin as anti-viral	26
2.3	DNA biosynthesis	28
2.3.1	Herpesvirus DNA polymerase - acyclovir and vidarabine as anti-virals	30
2.3.2	Mammalian DNA polymerase - cytarabine as anti-leukaemic	32
2.3.3	DNA topoisomerases	33
2.3.4	Reverse transcriptase - azidothymidine for AIDS	38
2.3.5	Bacterial RNA polymerase - rifampicin as antimycobacterial	40
2.4	Nucleotide catabolism	40
2.4.1	Adenosine deaminase - 2-deoxycoformycin as anti-leukaemic	41
2.4.2	Xanthine oxidase - allopurinol for gout	43
2.4.3	Guanylate cyclase	45
	Questions	46
	References	47
3.	Protein biosynthesis	51
3.1	Introduction	51
3.2	Aminoglycosides	54
3.3	Chloramphenicol	57
3.4	Tetracyclines	59
3.5	Erythromycin	60
3.6	Clindamycin	61
	Questions	62
	References	63
4.	Carbohydrate metabolism	65
4.1	Introduction	65
4.2	Metronidazole action - anaerobic protozoal and bacterial infections	66
4.3	Medical use of metronidazole	69
4.4	α -Glucosidase inhibitors - acarbose as antidiabetic	70
4.5	Sialidase inhibitor-4-guanidino-Neu5AcZen for influenza	71
	Questions	72
	References	72
5.	Cell wall biosynthesis	75
5.1	Introduction	75
5.2	β -lactams	77
5.2.1	Penicillin-binding proteins	78

5.2.2	β -Lactamases	81
5.2.3	β -Lactam therapy	84
5.3	Vancomycin	86
5.4	Mycolic acid synthesis - isoniazid for tuberculosis	88
5.5	β -Glucan synthetase	90
	Questions	90
	References	91
6.	Steroid biosynthesis and action	95
6.1	Introduction	95
6.2	Sterol biosynthesis	100
6.2.1	β -Hydroxy- β -methylglutaryl CoA reductase - lovastatin as hypocholesterolaemic	100
6.2.2	Squalene epoxidase - naftifine as anti-fungal	103
6.2.3	Lanosterol demethylation - ketoconazole as anti-fungal	104
6.3	Steroid biosynthesis	107
6.3.1	Steroid 17,20-lyase - ketoconazole for steroid-dependent tumours	107
6.3.2	11 β -Steroid hydroxylase - metyrapone for hypercortisolism	108
6.3.3	Aromatase - aminoglutethimide for hormone-dependent cancers	109
6.3.4	5 α -Reductase	110
6.4	Steroid receptor ligands	111
6.4.1	Oestrogen/progesterone receptor agonists - oral contraceptives	111
6.4.2	Oestrogen antagonists - tamoxifen for oestrogen-dependent cancer, clomiphene to stimulate ovulation	114
6.4.3	Progesterone antagonist - mifepristone as abortifacient	116
6.4.4	Androgen antagonist	116
6.4.5	Aldosterone antagonist - spironolactone as diuretic	117
	Questions	119
	References	120
7.	Prostaglandin and leukotriene biosynthesis and action	123
7.1	Introduction	123
7.2	Phospholipase inhibition - glucocorticoids for asthma and arthritis	124
7.3	Prostaglandin synthetase inhibitors - aspirin and other non-steroidal anti-inflammatories	127
7.4	Rheumatoid arthritis	130
7.5	Thromboxane synthesis	132

7.6	Leukotriene biosynthesis	132
	Questions	133
	References	133
8.	Zinc metalloenzymes	135
8.1	Introduction	135
8.2	Carbonic anhydrase - methazolamide for glaucoma	136
8.3	Angiotensin-converting enzyme	141
8.3.1	Angiotensin-converting enzyme inhibitors - captopril and enalapril for hypertension	145
8.3.2	Pharmacology of ACE inhibitors	146
8.4	Endopeptidase 24.11 - thiorphan as analgesic	148
	Questions	149
	References	150
9.	Neurotransmitter action and metabolism	151
9.1	Introduction	151
9.1.1	G-Protein linked receptor structure	154
9.1.2	Signal transduction and receptor occupancy	155
9.1.3	Drug development	159
9.2	Adrenergic receptors	160
9.2.1	α -Adrenergic receptors	161
9.2.2	β -Adrenergic receptors	163
9.2.3	Mixed α - and β -antagonist	166
9.3	Dopamine receptors	166
9.3.1	Dopamine agonists - L-dopa and bromocryptine for Parkinsonism, fenoldopam for hypertension	167
9.3.2	Dopamine antagonists - phenothiazines, butyrophenones and diphenylbutylpiperidines for schizophrenia	
9.4	Serotonin receptors	169
9.4.1	5HT _{1A} receptors, anxiety and depression	175
9.4.2	5HT _{1D} receptors and migraine	176
9.4.3	5HT ₂ receptors	178
9.4.4	5HT ₃ receptors	178
9.5	Serotonin and noradrenaline re-uptake mechanisms - tricyclic anti-depressants	180
9.6	Monoamine oxidase - tranylcypromine and moclobemide for depression, deprenyl for Parkinsonism	183
9.6.1	Monoamine oxidase and Parkinsonism	187
9.7	Acetylcholine action	188
9.7.1	Muscarinic receptor - pirenzepine for ulcers, atropine pre-anaesthetic medication, pilocarpine for glaucoma	189

9.7.2	Acetylcholinesterase - pyridostigmine for myasthenia gravis	192
9.8	4-Aminobutyric acid receptor - benzodiazepines as hypnotics, avermectin as antihelminthic, baclofen for spasticity	194
9.8.1	Benzodiazepines	195
9.8.2	Avermectin	197
9.8.3	Baclofen	200
9.9	Opiate receptors - morphine for pain	201
9.9.1	Opioid dependence	204
9.9.2	Pentazocine as analgesic	204
9.9.3	Loperamide as anti-diarrhoeal	205
9.10	Histamine receptors - mepyramine as anti-allergic, cimetidine as anti-ulcer	206
9.10.1	H_1 receptor antagonists	207
9.10.2	H_2 receptor antagonists	208
	Questions	210
	References	210
10.	Membrane-active agents	215
10.1	Introduction	215
10.1.1	Membrane structure	215
10.1.2	Dynamics of the heart beat	217
10.2	The sodium channel	219
10.2.1	Sodium channel blockers - procaine as a local anaesthetic	220
10.2.2	Anti-arrhythmic agents - lidocaine as an anti-arrhythmic	222
10.2.3	Diuretics - amiloride and triamterene	223
10.3	The calcium channel	225
10.3.1	Calcium channel antagonists - verapamil, nifedipine for hypertension and heart failure	227
10.4	Coupled sodium-chloride ion channels - furosemide and ethacrynic acid as diuretics	230
10.5	Membrane-bound ATPases	231
10.5.1	Sodium-potassium-ATPase - cardiac glycosides for heart failure	232
10.5.2	Potassium-hydrogen-ATPase - omeprazole for ulcers	236
10.6	Cromoglycate - calcium antagonist or membrane stabilizer?	239
10.6.1	Cromoglycate action	239
10.7	Cyclosporin	241
10.8	Potassium channel opening	243
10.9	Sterol ligands - polyene antibiotics	244
10.9.1	Amphotericin action	245
	Questions	247
	References	248

11.	Microtubule assembly	251
11.1	Introduction	251
11.2	Colchicine for gout	252
11.3	Vinca alkaloids as anti-tumour agents	255
11.4	Griseofulvin as an anti-fungal agent	256
11.5	Benzimidazoles as anthelmintics	257
11.6	Taxol as an anti-tumour agent	259
	Questions	260
	References	260
12.	Hormonal modulators	261
12.1	Introduction	261
12.2	Diabetes mellitus	261
	12.2.1 The action of insulin	262
	12.2.2 Insulin therapy	264
12.3	Sulphonylureas as hypoglycaemic agents	266
12.4	Gonadotrophin-hormone-releasing hormone (GnRH) analogues	268
	Questions	273
	References	273
Appendix: Quantification of ligand-macromolecule binding		275
A.1	Enzyme kinetics: I_{50} or K_i ?	275
A.2	Drug binding to receptors	278
A.3	Ligand-protein binding	280
	References	282
Index		285